MultiCell Technologies, Inc.
68 Cumberland Street
Suite 301
Woonsocket,
RI 02895
United States - Map
Phone: 401-762-0045
Fax: 401-762-0098
Web Site: http://www.multicelltech.com
| MultiCell Technologies, Inc., a biopharmaceutical company, develops and commercializes therapeutics based on a portfolio of patented drug development technology platforms. It involves in the research and development of degenerative neurological diseases, including multiple sclerosis (MS) and cancer. The companys therapeutic pipeline includes MCT-125, a Phase IIb therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-175, a preclinical therapeutic candidate for the treatment of relapsing-remitting MS; MCT-465, a preclinical adjuvant therapeutic candidate for the treatment of TLR3+ cancers; and MCT-475, a preclinical therapeutic candidate for the treatment of TLR3+ breast cancer. In addition, it has patented the Sybiol synthetic bio-liver device to produce therapeutic proteins using BioFactories technology. The company was formerly known as Exten Ventures, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is based in Woonsocket, Rhode Island. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. W. Gerald Newmin , 72
Chairman, Chief Exec. Officer, Pres, Chief Financial Officer, Sec. and Treasurer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.01% Nasdaq 0.00%
Profile
